Herpes simplex virus (HSV-1) is a common pathogen that causes skin and venereal diseases. To date, a cure for this pathogen does not exist. Therefore, the development of a vaccine to prevent infection with the virus seems to be the best solution. DNA vaccines represent a novel vaccine formulation, which is able to induce an immune response. In the present study, we used genetic engineering technologies to ligate the HSV-1 protein Vp23 into the pcDNA3.1 plasmid, resulting in the constructed plasmid pcDNA3.1-UL18, the potential DNA vaccine against HSV- 1.The pcDNA3.1-UL18 (p-Vp23) was used for mice immunization. Determination of serum IgG levels, serum neutralization antibody titers, proliferation of spleen lymphocytes, Delayed Hypersensitivity Test reaction, as well as detection of the inflammatory factors IFN-, IL-2, IL-4 and IL-10 in spleen cells revealed that the constructed p-Vp23, to a certain extent, was able to induce immune response in mice.